By contrast, there were no significant differences in the efficacy between afatinib and the combination of afatinib with simvastatin in patients with nonadenocarcinomatous NSCLC, which is unlikely to have EGFR mutations [113]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.